{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Castration-Resistant&page=20",
    "query": {
      "condition": "Castration-Resistant",
      "page": 20
    },
    "page_size": 10
  },
  "pagination": {
    "page": 20,
    "page_size": 10,
    "total_count": 667,
    "total_pages": 67,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Castration-Resistant&page=21&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Castration-Resistant&page=19&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T14:06:11.284Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04691804",
      "title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Castration-Resistant Prostate Cancer (mCRPC)"
      ],
      "interventions": [
        {
          "name": "Fuzuloparib , Abiraterone acetate and Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Fuzuloparib Placebo， Abiraterone acetate and Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jiangsu HengRui Medicine Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 496,
      "start_date": "2021-03-18",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-12-31",
      "last_synced_at": "2026-10-30T14:06:11.284Z",
      "location_count": 17,
      "location_summary": "Anchorage, Alaska • Tucson, Arizona • Rancho Mirage, California + 13 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "San Bernardino",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04691804"
    },
    {
      "nct_id": "NCT03999515",
      "title": "Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castration-Resistant Prostate Carcinoma",
        "Double-Negative Prostate Carcinoma",
        "Metastatic Prostate Carcinoma",
        "Prostate Adenocarcinoma",
        "Stage IV Prostate Cancer AJCC v8",
        "Stage IVA Prostate Cancer AJCC v8",
        "Stage IVB Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Erdafitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 3,
      "start_date": "2020-04-27",
      "completion_date": "2021-06-06",
      "has_results": true,
      "last_update_posted_date": "2023-09-28",
      "last_synced_at": "2026-10-30T14:06:11.284Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03999515"
    },
    {
      "nct_id": "NCT06100705",
      "title": "Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Testosterone Cypionate",
          "type": "DRUG"
        },
        {
          "name": "Sipuleucel-T",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2023-12-20",
      "completion_date": "2028-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-10-30T14:06:11.284Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06100705"
    },
    {
      "nct_id": "NCT01995513",
      "title": "Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 509,
      "start_date": "2013-10-22",
      "completion_date": "2022-08-31",
      "has_results": true,
      "last_update_posted_date": "2023-09-18",
      "last_synced_at": "2026-10-30T14:06:11.284Z",
      "location_count": 6,
      "location_summary": "Boston, Massachusetts • Philadelphia, Pennsylvania • Virginia Beach, Virginia",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01995513"
    },
    {
      "nct_id": "NCT01848067",
      "title": "Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Prostate",
        "Hormone-resistant Prostate Cancer",
        "Recurrent Prostate Cancer",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Alisertib",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone acetate",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 9,
      "start_date": "2013-08-14",
      "completion_date": "2016-06-23",
      "has_results": true,
      "last_update_posted_date": "2025-05-04",
      "last_synced_at": "2026-10-30T14:06:11.284Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01848067"
    },
    {
      "nct_id": "NCT04237584",
      "title": "A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Enzalutamide during Lead-in Period",
          "type": "DRUG"
        },
        {
          "name": "Lead-in Enzalutamide followed by Radium-223/Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Lead-in Enzalutamide followed by Placebo/Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Darolutamide during Lead-in Period",
          "type": "DRUG"
        },
        {
          "name": "Lead-in Darolutamide followed by Radium-223/Darolutamide",
          "type": "DRUG"
        },
        {
          "name": "Lead-in Darolutamide followed by Placebo/Darolutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MANA RBM",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 23,
      "start_date": "2020-06-30",
      "completion_date": "2022-03-07",
      "has_results": true,
      "last_update_posted_date": "2022-10-07",
      "last_synced_at": "2026-10-30T14:06:11.284Z",
      "location_count": 1,
      "location_summary": "Myrtle Beach, South Carolina",
      "locations": [
        {
          "city": "Myrtle Beach",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04237584"
    },
    {
      "nct_id": "NCT03016741",
      "title": "Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Castration-Resistant Prostatic Cancer",
        "Metastatic Prostate Carcinoma",
        "Recurrent Prostate Carcinoma",
        "Stage IV Prostate Cancer",
        "Hormone-Refractory Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "GnRH agonist/antagonist",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 100,
      "start_date": "2017-03-31",
      "completion_date": "2029-08",
      "has_results": false,
      "last_update_posted_date": "2026-02-24",
      "last_synced_at": "2026-10-30T14:06:11.284Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03016741"
    },
    {
      "nct_id": "NCT03454451",
      "title": "CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Renal Cell Cancer",
        "Colorectal Cancer",
        "Triple Negative Breast Cancer",
        "Cervical Cancer",
        "Ovarian Cancer",
        "Pancreatic Cancer",
        "Endometrial Cancer",
        "Sarcoma",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Bladder Cancer",
        "Metastatic Castration Resistant Prostate Cancer",
        "Non-hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "CPI-006",
          "type": "DRUG"
        },
        {
          "name": "CPI-006 + ciforadenant",
          "type": "DRUG"
        },
        {
          "name": "CPI-006 + pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corvus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 117,
      "start_date": "2018-04-25",
      "completion_date": "2023-02-19",
      "has_results": false,
      "last_update_posted_date": "2023-12-21",
      "last_synced_at": "2026-10-30T14:06:11.284Z",
      "location_count": 22,
      "location_summary": "Tucson, Arizona • Duarte, California • San Francisco, California + 18 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03454451"
    },
    {
      "nct_id": "NCT03480646",
      "title": "ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration Resistant Prostate Cancer (mCRPC)"
      ],
      "interventions": [
        {
          "name": "CPI-1205",
          "type": "DRUG"
        },
        {
          "name": "Cobicistat",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Constellation Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 175,
      "start_date": "2017-11-15",
      "completion_date": "2021-02-03",
      "has_results": true,
      "last_update_posted_date": "2025-10-29",
      "last_synced_at": "2026-10-30T14:06:11.284Z",
      "location_count": 41,
      "location_summary": "Anchorage, Alaska • Beverly Hills, California • Duarte, California + 34 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03480646"
    },
    {
      "nct_id": "NCT07219147",
      "title": "177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Castration-Resistant Prostate Adenocarcinoma",
        "Stage IVB Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Leukapheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Lutetium Lu 177 Vipivotide Tetraxetan",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "PSMA PET Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Sipuleucel-T",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2026-03-06",
      "completion_date": "2028-07-26",
      "has_results": false,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-10-30T14:06:11.284Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07219147"
    }
  ]
}